InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.41
(
0.46%
)
Bitcoin
62,807.43
(
-0.56%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

rfj1862

Send PM Follow Ignore
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

rfj1862

Re: None

Thursday, 06/20/2019 10:23:45 AM

Thursday, June 20, 2019 10:23:45 AM

Post# of 252311
And here is an embarrassingly terrible writeup of MRKR from a guy selling a $399/year biotech analysis service on Seeking Alpha who doesn't even have a basic grasp of the biotech industry, molecular biology, or clinical trials. If nothing else it serves as an example of why Seeking Alpha's model is fundamentally flawed.

I posted some criticism of this on the MRKR board but it was immediately deleted--the author is a moderator on the board.

https://seekingalpha.com/article/4271106-marker-therapeutics-cell-therapy-biotech-thinking-outside-box
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up